瑞士制药巨头诺华与生物技术公司Monte Rosa签署一项总价值高达57亿美元的许可协议,用于开发治疗免疫介导疾病的药物。根据协议,Monte Rosa将获得1.2亿美元的预付款。该公司股价美股盘前大涨50%。
瑞士制药巨头诺华与生物技术公司Monte Rosa签署一项总价值高达57亿美元的许可协议,用于开发治疗免疫介导疾病的药物。根据协议,Monte Rosa将获得1.2亿美元的预付款。该公司股价美股盘前大涨50%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.